218 related articles for article (PubMed ID: 25877301)
1. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD.
Yu W; Wang G; Li LX; Zhang H; Gui X; Zhou JX; Calvet JP; Li X
Hum Mol Genet; 2023 Mar; 32(7):1114-1126. PubMed ID: 36322156
[TBL] [Abstract][Full Text] [Related]
3. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
4. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Smithline ZB; Nikonova AS; Hensley HH; Cai KQ; Egleston BL; Proia DA; Seeger-Nukpezah T; Golemis EA
PLoS One; 2014; 9(12):e114403. PubMed ID: 25474361
[TBL] [Abstract][Full Text] [Related]
6. PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression.
Lakhia R; Ramalingam H; Chang CM; Cobo-Stark P; Biggers L; Flaten A; Alvarez J; Valencia T; Wallace DP; Lee EC; Patel V
Nat Commun; 2022 Aug; 13(1):4765. PubMed ID: 35965273
[TBL] [Abstract][Full Text] [Related]
7. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.
McCleland ML; Mesh K; Lorenzana E; Chopra VS; Segal E; Watanabe C; Haley B; Mayba O; Yaylaoglu M; Gnad F; Firestein R
J Clin Invest; 2016 Feb; 126(2):639-52. PubMed ID: 26752646
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
9. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury.
Saiz ML; Lozano-Chamizo L; Florez AB; Marciello M; Diaz-Bulnes P; Corte-Iglesias V; Bernet CR; Rodrigues-Diez RR; Martin-Martin C; Rodriguez-Santamaria M; Fernandez-Vega I; Rodriguez RM; Diaz-Corte C; Suarez-Alvarez B; Filice M; Lopez-Larrea C
Biomed Pharmacother; 2024 May; 174():116492. PubMed ID: 38537579
[TBL] [Abstract][Full Text] [Related]
10. CD74 Promotes Cyst Growth and Renal Fibrosis in Autosomal Dominant Polycystic Kidney Disease.
Zhou JX; Cheng AS; Chen L; Li LX; Agborbesong E; Torres VE; Harris PC; Li X
Cells; 2024 Mar; 13(6):. PubMed ID: 38534333
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
12. BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis.
Dong X; Hu X; Chen J; Hu D; Chen LF
Cell Death Dis; 2018 Feb; 9(2):203. PubMed ID: 29434197
[TBL] [Abstract][Full Text] [Related]
13. Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning.
Wang J; Yang W; Zhao L; Wei B; Chen J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675678
[TBL] [Abstract][Full Text] [Related]
14. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
De Raedt T; Beert E; Pasmant E; Luscan A; Brems H; Ortonne N; Helin K; Hornick JL; Mautner V; Kehrer-Sawatzki H; Clapp W; Bradner J; Vidaud M; Upadhyaya M; Legius E; Cichowski K
Nature; 2014 Oct; 514(7521):247-51. PubMed ID: 25119042
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of SMYD3 Promotes Autosomal Dominant Polycystic Kidney Disease by Mediating Cell Proliferation and Genome Instability.
Agborbesong E; Zhou JX; Zhang H; Li LX; Harris PC; Calvet JP; Li X
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540216
[TBL] [Abstract][Full Text] [Related]
16. BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10.
Ma Y; Liu N; Shi Y; Ma S; Wang Y; Zheng W; Sun R; Song Y; Chen M; Qu L; Mao R; Fan Y
Cell Signal; 2024 Jul; 119():111173. PubMed ID: 38604343
[TBL] [Abstract][Full Text] [Related]
17. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.
Jakobsen ST; Jensen RAM; Madsen MS; Ravnsborg T; Vaagenso CS; Siersbæk MS; Einarsson H; Andersson R; Jensen ON; Siersbæk R
Nat Genet; 2024 Apr; 56(4):663-674. PubMed ID: 38454021
[TBL] [Abstract][Full Text] [Related]
18. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma.
Das D; Leung JY; Balamurugan S; Tergaonkar V; Loh AHP; Chiang CM; Taneja R
EMBO Rep; 2024 Feb; 25(2):832-852. PubMed ID: 38191874
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer.
Ding D; Zheng R; Tian Y; Jimenez R; Hou X; Weroha SJ; Wang L; Shi L; Huang H
Nat Commun; 2022 Oct; 13(1):6311. PubMed ID: 36274096
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of asymmetric cell division by the LIBR-BRD4 axis.
Chen HF; Chang CT; Hsu KW; Peng PH; Lai JC; Hung MC; Wu KJ
Nucleic Acids Res; 2024 Jan; 52(1):154-165. PubMed ID: 37986225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
